Extract
In response to our manuscript on the eligibility for shorter treatment of multidrug-resistant tuberculosis (MDR-TB) in the European Union (EU) [1], Heldal and co-workers highlight the limitations of the surveillance data that were used to estimate the proportion of MDR-TB cases eligible for the shorter regimen, and they question the criteria that we used to define eligibility.
Abstract
Strict application of criteria shows that 11% of MDR-TB cases are eligible for the shorter MDR-TB regimen in the EU http://ow.ly/p9aq30bt1AI
Footnotes
Conflict of interest: None declared.
- Received March 6, 2017.
- Accepted March 9, 2017.
- Copyright ©ERS 2017